Phase II study of neo-adjuvant gemcitabine plus epirubicin in primarily unresectable locally advanced breast cancer.
Silva
Juan Alejandro
JA
Pérez
Mario
M
Rivera
Samuel
S
Olivares
Guillermo
G
Lira-Puerto
Victor
V
Castañeda
Noel
N
Morales
Flavia
F
Calderillo
Germán
G
Alcedo
Juan Carlos
JC
Oñate-Ocaña
F
F
Gallardo
Dolores
D
De La Garza
Jaime
J
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000473:pathology / Q000628:therapy*; D003841:Deoxycytidine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*; D018450:Disease Progression; D015251:Epirubicin / Q000008:administration & dosage* / Q000009:adverse effects; D005260:Female; D006801:Humans; D007970:Leukopenia / Q000139:chemically induced; D015412:Mastectomy, Segmental; D008875:Middle Aged; D020360:Neoadjuvant Therapy; D016896:Treatment Outcome; D000093542:Gemcitabine
D003841:Deoxycytidine; D015251:Epirubicin; D000093542:Gemcitabine